Navigation Links
Bionovo to Present Positive Results from Phase 2 Trial of Menerba for Vasomotor Symptoms to the International Community
Date:9/3/2009

, with an improved safety profile compared to traditional hormone therapy. The clinical trial results have been evaluated by an independent Data and Safety Monitoring Board and the drug candidate has passed through a standard two-phase examination for safety.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticip
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Bionovo Presents Positive Results from Phase 1B Trial of Bezielle for Metastatic Breast Cancer
2. Bionovo to Present at the BMO Capital Markets Ninth Annual Focus on Healthcare Conference
3. Bionovo Announces Arbitration Decision in Lawsuit Filed by Former Officer - All Claims Denied
4. Bionovo, Inc. to Announce First Quarter Fiscal Year 2009 Financial Results on Thursday, May 7, 2009
5. Bionovo to Present at the Cambria Capital Investor Meeting
6. Bionovo to Present at Wall Street Analyst Forums 20th Annual Institutional Investor Conference
7. Bionovo, Inc. to Announce Fourth Quarter and Year-End Financial Results on Thursday, March 12, 2009
8. Jan Ake Gustafsson, M.D., Ph.D., Joins Bionovos Scientific Advisory Board
9. Bionovo Announces Presentation at the National Cancer Institute
10. Bionovo Announces Cost Control Measures Taken
11. Willa A. Hsueh, M.D., Joins Bionovos Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 14, 2014 Top nutritional supplement provider ... its Quality Control and Assurance Department. As the company ... additional, highly-qualified quality assurance (QA) and quality control (QC) ... which IQ Formulations has become known. , ... decades of stellar experience and qualifications to their new ...
(Date:7/14/2014)... SingaporeA*STAR,s Bioprocessing Technology Institute (BTI) has entered into ... pharmaceutical company, Roche, to identify novel drug candidates ... partnership brings together BTI,s capabilities in novel antibody ... (mAbs) therapeutics, opening up the possibility of ... death worldwide. , The collaboration makes use ...
(Date:7/14/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... MARKETS , the global synthetic biology market is ... 2018, with a five-year compound annual growth rate ... fastest growing segment, with anticipated $9.7 billion in ... the pharmaceutical/diagnostics, chemical, energy, and agricultural industries compose ...
(Date:7/14/2014)... Botanica Day Spa announced last month ... held at the day spa in down town Clearwater, ... and other refreshments will be served as clients are ... beauty products and great deals on spa services, ... , Dermaplaning (also known as “facial shaving”) is a ...
(Date:7/14/2014)... -- Along with improving vision, cataract surgery may slow ... types of dementia, a new study suggests. Better ... said. "These preliminary results indicate that improved vision ... dementia and their loved ones, both visual and non-visual," ... and University Hospitals Case Medical Center, in Ohio. ...
Breaking Medicine News(10 mins):Health News:Leading Health Supplement Company IQ Formulations Expands Quality Control and Assurance Department 2Health News:A*STAR partners Roche to develop new cancer therapeutics 2Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 2Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 3Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 3Health News:Cataract Surgery a Plus for Someone With Dementia, Study Says 2
... SOUTH SAN FRANCISCO, Calif., May 13 Rigel Pharmaceuticals, Inc. ... Gower, the company,s chairman and chief executive officer, is scheduled ... Securities Research Conference in San Francisco on Wednesday, May 20th ... the subsequent archived recording, log on to www.rigel.com . ...
... Science Olympiad to Emphasize the Importance of Fueling Body ... you find America,s brightest young minds launching rockets, crashing ... are part of the 25th annual Science Olympiad National ... first time, the incredible edible egg, on behalf of ...
... Gastroenterologist Offers Tips for Treatment , ... San Bruno, CA (PRWEB) May ... (AGE) affect Americans each year, according to eMedicine from WebMD. ... a viral, bacterial or parasitic infection. Victims are usually hit by ...
... medical search engine will debut on 16 May 2009 at the ... , ... Budapest, Hungary (PRWEB) May 13, 2009 -- Existing ... information to consumers. WebLib CEO Endre Jofoldi notes that "the goal ...
... ( BOVESPA: AMIL3, Bloomberg: AMIL3 BZ and Reuters: AMIL3.SA ... its results for the first quarter of 2009. ... stood at 3.11 million, 9.7% up on the 1Q08 ... 4Q08.Adjusted Operating Revenues totaled R$ 1,131 million in ...
... Adding B vitamin to grain products cut congenital heart defects ... -- Since the mandatory addition of folic acid to flour, ... than a decade ago, fewer babies have been born with ... of vitamin B, has been shown to reduce neural tube ...
Cached Medicine News:Health News:America's Top Young Scientists to Receive Scholarships for Winning Eggs-Periments 2Health News:America's Top Young Scientists to Receive Scholarships for Winning Eggs-Periments 3Health News:America's Top Young Scientists to Receive Scholarships for Winning Eggs-Periments 4Health News:When Stomach Flu Strikes, Work With, Not Against, Body's Natural Defenses 2Health News:Amilpar - Revenue Increases 13.4% and Medical Loss Ratio Falls in the First Quarter 2009 2Health News:Folic Acid Reduces Infant Heart Defects 2
(Date:7/14/2014)... Valeant Pharmaceuticals International, Inc. (NYSE: ... it has filed a premerger notification under the ... the U.S. Federal Trade Commission (FTC) relating to ... About Valeant Pharmaceuticals International, Inc. ... VRX) is a multinational specialty pharmaceutical company that ...
(Date:7/14/2014)... , July 14, 2014 Synthetic ... technology partnership with global bioengineering leader DNA2.0, ... for quick-to-market products. The integration ... machine learning optimization technologies, such as ProteinGPS™ ... process of engineering proteins in the Pareto ...
(Date:7/14/2014)... 2014  Abbott (NYSE: ABT) announced today that it will ... Mylan for equity ownership of a newly formed entity ... Abbott,s developed markets pharmaceuticals business, and will ... of approximately $5.3 billion based on Mylan,s closing stock ... business generated approximately $2 billion in sales in 2013. ...
Breaking Medicine Technology:Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 2Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 3Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 4Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 5Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 2Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 3Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 2Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 3Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 4Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 5Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 6Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 7
... /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA ), ... it has filed its Annual Report on Form 20-F with ... December 31, 2010 on April 22, 2011.  The Annual Report ... The Company will provide a hard copy of ...
... The following release is being issued by law ... Feldman & Pinto: According to two new ... Medical Journal, Bayer,s birth control pills Yaz and Yasmin, ... triple the risk of serious blood clots (known as ...
Cached Medicine Technology:Sinovac Files Annual Report on Form 20-F 2
Sheath Introducers with guidewires....
... design, utilizing an advanced cobalt-based ... stainless steel stents. This stronger ... for unparalleled flexibility plus optimal ... Stent Systemwith thin struts that ...
... Catheter provides support to enhance the ... adverse conditions. It gives you dependable ... your destination in cardiac interventions. It ... of clinical situations and the most ...
... Xtra, and Maximum ACT introducers represent ... specialty hemostasis introducers in the world. ... hemostasis introducers for use in interventional ... angioplasty, stenting, atherectomy, temporary pacing, endomyocardial ...
Medicine Products: